Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

The Journal of Headache and Pain

Research Article

Fayyaz Ahmed¹  Victoria Quarshie²  Modar Khalil³  Hassan W Zafar³ 

[1] Consultant Neurologist, Hull Royal Infirmary, Anlaby Road, HU3 2JZ, Hull, UK;Specialist Headache Nurse, Hull Royal Infirmary, Anlaby Road, HU3 2JZ, Hull, UK;Specialist Registrar in Neurology, Hull Royal Infirmary, Anlaby Road, HU3 2JZ, Hull, UK;

关键词: Migraine;    National Health Service;    Chronic Migraine;    Medication Overuse;    Episodic Migraine;   

DOI  :  10.1186/1129-2377-15-54

 received in 2014-06-05, accepted in 2014-08-06,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundChronic migraine affects 2% of the population. It results in substantial disability and reduced quality of life. Medications used for prophylaxis in episodic migraine may also work in chronic migraine. The efficacy and safety of OnabotulinumtoxinA (BOTOX) in adults with chronic migraine was confirmed in the PREEMPT programme. However, there are few real-life data of its use.Method254 adults with chronic migraine were injected with OnabotulinumtoxinA BOTOX as per PREEMPT Protocol between July 2010 and May 2013, their headache data were collected using the Hull headache diary and analysed to look for headache, migraine days decrements, crystal clear days increment in the month post treatment, we looked at the 50% responder rate as well.ResultsOur prospective analysis shows that OnabotulinumtoxinA, significantly, reduced the number of headache and migraine days, and increased the number of headache free days. OnabotulinumtoxinA Botox also improved patients’ quality of life. We believe that these results represent the largest post-marketing cohort of patients treated with OnabotulinumtoxinA in the real-life clinical setting.ConclusionOnabotulinumtoxinA is a valuable addition to current treatment options in patients with chronic migraine. Our results support findings of PREEMPT study in a large cohort of patients, we believe, is representative of the patients seen in an average tertiary headache centre. While it can be used as a first line prophylaxis its cost may restrict its use to more refractory patients who failed three oral preventive treatments.

【 授权许可】

Unknown   
© Khalil et al.; licensee Springer. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.